Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Faster Drug Approvals Are Not Always Better and Can Be Worse

Faster Drug Approvals Are Not Always Better and Can Be Worse Research Original Investigation Association Between Surrogate End Points and Survival in Oncology Follow-up of applications submitted to two 94. Chapman PB, Hauschild A, Robert C, et al; 100. Prasad V, Grady C. The misguided ethics of institutional review boards. JAMA. 1992;267(3): BRIM-3 Study Group. Improved survival with crossover trials. Contemp Clin Trials. 2014;37(2): 374-378. vemurafenib in melanoma with BRAF V600E 167-169. mutation. N Engl J Med. 2011;364(26):2507-2516. 90. Dwan K, Altman DG, Arnaiz JA, et al. 101. Lakdawalla DN, Chou JW, Linthicum MT, Systematic review of the empirical evidence of 95. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib MacEwan JP, Zhang J, Goldman DP. Evaluating study publication bias and outcome reporting bias. malate for the treatment of pancreatic expected costs and benefits of granting access to PLoS One. 2008;3(8):e3081. neuroendocrine tumors. N Engl J Med. 2011;364(6): new treatments on the basis of progression-free 501-513. survival in non–small-cell lung cancer [published 91. Rising K, Bacchetti P, Bero L. Reporting bias in online March 19, 2015]. JAMA Oncol. doi:10.1001 drug trials submitted to the Food and Drug 96. Kantoff PW, Higano CS, Shore ND, et al; /jamaoncol.2015.0203. Administration: review of publication and IMPACT Study Investigators. Sipuleucel-T presentation. PLoS Med. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Faster Drug Approvals Are Not Always Better and Can Be Worse

JAMA Internal Medicine , Volume 175 (8) – Aug 1, 2015

Faster Drug Approvals Are Not Always Better and Can Be Worse

Abstract

Research Original Investigation Association Between Surrogate End Points and Survival in Oncology Follow-up of applications submitted to two 94. Chapman PB, Hauschild A, Robert C, et al; 100. Prasad V, Grady C. The misguided ethics of institutional review boards. JAMA. 1992;267(3): BRIM-3 Study Group. Improved survival with crossover trials. Contemp Clin Trials. 2014;37(2): 374-378. vemurafenib in melanoma with BRAF V600E 167-169. mutation. N Engl J Med. 2011;364(26):2507-2516. 90. Dwan K,...
Loading next page...
 
/lp/american-medical-association/faster-drug-approvals-are-not-always-better-and-can-be-worse-XZU39Ei27Y

References (15)

Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2015.2857
pmid
26098077
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Association Between Surrogate End Points and Survival in Oncology Follow-up of applications submitted to two 94. Chapman PB, Hauschild A, Robert C, et al; 100. Prasad V, Grady C. The misguided ethics of institutional review boards. JAMA. 1992;267(3): BRIM-3 Study Group. Improved survival with crossover trials. Contemp Clin Trials. 2014;37(2): 374-378. vemurafenib in melanoma with BRAF V600E 167-169. mutation. N Engl J Med. 2011;364(26):2507-2516. 90. Dwan K, Altman DG, Arnaiz JA, et al. 101. Lakdawalla DN, Chou JW, Linthicum MT, Systematic review of the empirical evidence of 95. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib MacEwan JP, Zhang J, Goldman DP. Evaluating study publication bias and outcome reporting bias. malate for the treatment of pancreatic expected costs and benefits of granting access to PLoS One. 2008;3(8):e3081. neuroendocrine tumors. N Engl J Med. 2011;364(6): new treatments on the basis of progression-free 501-513. survival in non–small-cell lung cancer [published 91. Rising K, Bacchetti P, Bero L. Reporting bias in online March 19, 2015]. JAMA Oncol. doi:10.1001 drug trials submitted to the Food and Drug 96. Kantoff PW, Higano CS, Shore ND, et al; /jamaoncol.2015.0203. Administration: review of publication and IMPACT Study Investigators. Sipuleucel-T presentation. PLoS Med.

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Aug 1, 2015

There are no references for this article.